A once-nightly oral pill helped control obstructive sleep apnea in a large, phase 3 clinical trial presented at the 2026 ATS International Conference. The drug, called AD109, is the first therapy to treat OSA by addressing its underlying mechanisms and targeting the neuromuscular causes of airway collapse. “Aroxybutynin and Atomoxetine (AD109) for Obstructive Sleep Apnea: A Randomized Phase 3 Trial” will be published in the American Journal of Respiratory and Critical Care Medicine.

This study explores how healthy young adults’ brains adapt to visual occlusion during walking. Using Bangerter foils, resting-state functional magnetic resonance imaging (rs-fMRI), and pattern-reversal visual evoked potentials (PR-VEPs), it finds that walking activated key visuomotor pathways. Visual impairment strengthens functional connectivity between the right precentral and middle frontal gyri as compensation. The findings offer new potential targets for motor rehabilitation in low-vision populations.

Temporomandibular joint (TMJ) pain is associated with disrupted gut microbiome metabolites. Researchers reveal that butyrate, administered as tributyrin, alleviates pain by restoring histone acetylation and reversing gene regulatory changes in the brain. The team identified key genes involved in pain modulation, such as Nop14 using a mouse model as well as single-cell multi-omics sequencing. Targeting butyrate-related epigenetic pathways may offer a promising non-opioid strategy for treating TMJ pain.

A newly identified molecular pathway helps maintain the integrity of the bones in the skull and the face. Using mouse models, the study showed that loss of PTH1R signaling in periodontal cells triggers abnormal cementum overgrowth, severe periodontal ligament damage, and pathological tooth-bone fusion known as ankylosis. The findings uncover previously unknown mechanisms regulating adult periodontal tissue maintenance and may support future therapies for eruption disorders, ankylosis, and other periodontal diseases linked to abnormal mineralization.

High-altitude exposure, characterized by hypobaric hypoxia, cold, and intense radiation, profoundly remodels the gut microbiota, triggering a cascade of physiological and pathological changes that extend far beyond the gastrointestinal tract. As millions travel to or reside in regions above 2500 meters, understanding this gut-centric axis has become critical for managing health risks. Hypoxia disrupts the delicate balance of the gut ecosystem, leading to dysbiosis, impaired barrier function, and increased intestinal permeability. This allows bacterial translocation and systemic inflammation, which underpin conditions like acute and chronic mountain sickness. Crucially, the gut microbiome acts as a dynamic environmental sensor; its altered production of metabolites—particularly short-chain fatty acids (SCFAs) and bile acids—directly influences host energy metabolism, immune responses, and acclimatization capacity. These changes are increasingly implicated in a spectrum of diseases, from metabolic disorders to colorectal cancer, positioning the gut as a central mediator of high-altitude health. This review synthesizes evidence from human and animal studies to elucidate how high-altitude stress reshapes the microbial landscape, explores the mechanisms linking microbiota to disease, and evaluates emerging microbiome-based interventions for promoting resilience.